HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Abstract
Prognostic models for multiple myeloma have been fraught with tremendous heterogeneity in outcome among subgroups. In the context of Total Therapy 2, a tandem transplant trial for newly diagnosed myeloma, comprehensive information was available in 220 patients on standard prognostic factors (SPF), magnetic resonance imaging (MRI)-defined focal lesions, cytogenetic abnormalities (CA), fluorescence-in-situ-hybridisation (FISH)-derived amplification of chromosome 1q21 (amp1q21) and deletion of 13q14, as well as gene expression profiling (GEP). Five multivariate analysis-based survival models were derived, utilising SPF only (model 1), with progressive addition of CA (model 2), MRI (model 3), FISH (model 4) and GEP (model 5). The R(2) value, a measure of accounting for clinical outcome variability, increased progressively from 18% in model 1 to 38% in model 5. The hazard ratio for overall survival was highest for GEP (3.07, P < 0.001) followed by amp1q21 (1.71, P = 0.05). According to the presence of none (49%), one (35%) or both of these two risk features (16%), 3-year survival decreased progressively from 92% to 78% to 43% (P < 0.0001). Thus, the dominance over other prognostic parameters of molecular genetics justifies the generation of quantitative reverse transcription polymerase chain reaction methodology ('MM genetic kit') for the optimal risk stratification of patients participating in therapeutic trials.
AuthorsJohn D Shaughnessy Jr, Jeffrey Haessler, Frits van Rhee, Elias Anaissie, Mauricio Pineda-Roman, Michele Cottler-Fox, Klaus Hollmig, Maurizio Zangari, Abid Mohiuddin, Yazan Alsayed, Monica Grazziutti, Joshua Epstein, John Crowley, Bart Barlogie
JournalBritish journal of haematology (Br J Haematol) Vol. 137 Issue 6 Pg. 530-6 (Jun 2007) ISSN: 0007-1048 [Print] England
PMID17489983 (Publication Type: Journal Article)
Topics
  • Adult
  • Aged
  • Chromosome Deletion
  • Chromosomes, Human, Pair 1
  • Cytogenetic Analysis
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Gene Expression Profiling
  • Humans
  • In Situ Hybridization, Fluorescence
  • Kaplan-Meier Estimate
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Models, Statistical
  • Multiple Myeloma (drug therapy, genetics, mortality)
  • Multivariate Analysis
  • Prognosis
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: